Condition (MeSH)
Pancytopenia
ClinicalTrials.gov lists 21 trials for Pancytopenia or a narrower condition beneath it. National Heart, Lung, and Blood Institute (NHLBI) has the most among industry and government lead sponsors, with 9.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
21 of the 21 trials are tagged with Pancytopenia itself; the rest are tagged with a narrower condition beneath it.
When did Pancytopenia trials start? (12)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2024 | 1 |
| 2022 | 2 |
| 2018 | 3 |
| 2015 | 1 |
| 2014 | 1 |
| 2013 | 1 |
| 2012 | 1 |
| 2010 | 2 |
| 2005 | 1 |
Showing 10 of 12 earlier years.
No forecast is made for this condition: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 21 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Pancytopenia trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 4 |
| Phase 2 | 4 |
| Phase 3 | 1 |
| Not applicable | 1 |
| Observational | 8 |
| Expanded access | 1 |
How many Pancytopenia trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 2 |
| Active, not recruiting | 2 |
| Completed | 11 |
| No longer available | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Pancytopenia trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | 9 |
| Novartis Pharmaceuticals | 2 |
| Dren Bio | 1 |
| National Institute of Dental and Craniofacial Research (NIDCR) | 1 |
Which drugs are being tested for Pancytopenia? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cytoxan | 2 |
| Eltrombopag | 2 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)] | 3 |
| Cyclosporine 0.05% | 2 |
| Eltrombopag 12.5 mg | 1 |
| Cohort 2: hATG, CsA, EPAG Day 14 to Month 3 | 1 |
| Extension Cohort | 1 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Pancytopenia trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Febrile neutropenia | 15 | 3 |
| Serum sickness | 12 | 2 |
| Infection (documented clinically or microbiologically with grade 3 or 4 neutropenia) | 9 | 1 |
| Febril neutropenia | 8 | 1 |
| Pnuemonia | 7 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Pancytopenia? (51)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Long-term outcomes of patients with refractory cytopenia of childhood under observation only. | Blood advances | 2025 | Yes |
| A rare homozygous variant in TERT gene causing variable bone marrow failure, fragility fractures, rib anomalies and extremely short telomere lengths with high serum IgE. | British journal of haematology | 2024 | Yes |
| Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline. | British journal of haematology | 2024 | Yes |
| The distribution and accumulation of the shortest telomeres in telomere biology disorders. | British journal of haematology | 2023 | Yes |
| Noncirrhotic Portal Hypertension: Current and Emerging Perspectives. | Clinics in liver disease | 2019 | Yes |
Showing 5 of 51 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.